Latent tuberculosis – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:30:19 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Latent tuberculosis – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study Comparing Rifampicin, Isoniazid, and Rifapentine Regimens for Treating Latent Tuberculosis in Patients with End-Stage Kidney Disease https://clinicaltrials.eu/trial/study-comparing-rifampicin-isoniazid-and-rifapentine-regimens-for-treating-latent-tuberculosis-in-patients-with-end-stage-kidney-disease/ Wed, 29 Apr 2026 14:25:56 +0000 https://clinicaltrials.eu/trial/study-comparing-rifampicin-isoniazid-and-rifapentine-regimens-for-treating-latent-tuberculosis-in-patients-with-end-stage-kidney-disease/ This clinical trial is focused on treating latent tuberculosis infection in patients who have end-stage kidney disease. Latent tuberculosis infection means that the bacteria causing tuberculosis are present in the body but are not currently causing symptoms. End-stage kidney disease is a severe form of kidney disease where the kidneys are no longer able to work as they should. The study is testing three different treatment plans to see which one helps patients complete their treatment most effectively. The treatments being tested include three months of daily isoniazid plus rifampicin (known as 3HR), three months of once-weekly isoniazid plus rifapentine (known as 3HP), and four months of daily rifampicin (known as 4R).

The purpose of the study is to find out if the 3HP or 4R treatment plans are better than the 3HR plan for helping patients complete their treatment for latent tuberculosis infection. Participants in the study will be randomly assigned to one of these three treatment plans. The study will monitor how well participants stick to their assigned treatment over a period of time. The treatments involve taking medication by mouth, and the study will track how many doses are completed within a set timeframe.

Throughout the study, researchers will also look at other factors, such as whether participants stop their treatment due to side effects and the overall number of participants who pass away during the study. The study aims to provide valuable information on the best way to treat latent tuberculosis infection in patients with end-stage kidney disease, helping to improve care for these individuals in the future.

]]>